The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories Ltd. has announced the successful commissioning of its commercial scale manufacturing facility for pharma grade mPEG alcohols at its Cuernavaca facility in Mexico. mPEG alcohols are the key raw materials for activated mPEG, extensively used for pegylation with biologic drugs and increasingly for peptides and small molecule pharmaceuticals. Dr. Reddy’s has officially announced PEGtech as its product brand for its extensive range of activated mPEGs. The new assets in Mexico represent a significant investment in a dedicated facility operated to c-GMP standards which is capable of producing a wide range of molecular weight mPEGs and has a multi tonne annual capacity. The mPEG alcohol manufactured in Mexico will be supplied to Dr. Reddy’s c-GMP facility in Mirfield, UK where commercial scale activation is carried out.
PEGtech branding has been used to bring together a broad product range comprising a variety of activating groups and molecular weights (5-60 kDa), which are now fully supported by backward integration to the key starting materials. It furthermore highlights the company’s extensive experience in product development and GMP manufacture of the activated mPEGs. Commenting on the successful facility commissioning and PEGtech branding, Satish Reddy, MD and COO, Dr. Reddy’s said that the investment in the world class mPEG alcohol facility in Mexico underlines our commitment to the growing market for activated mPEGs. By introducing the PEGtech brand, our customers can be assured of the same high quality standards and customer service as they develop their PEGylated biologic drugs or small molecules from the laboratory right through to commercial applications.